A laboratory known as Valisure has filed a lawsuit in a U.S. court alleging that the organization that develops drug standards, U.S. Pharmacopeia (USP), made false and misleading statements about the lab’s testing methods. The lawsuit follows earlier public disputes in which Valisure clashed with regulators over impurities identified in some commonly used medicines; that prior history is presented in the reporting as context for the current legal action.
Valisure’s complaint centers on statements in a 2023 USP white paper. According to the reporting, the lab argues that USP inaccurately claimed Valisure employed “unvalidated methods” for quality testing. USP’s characterization, as described in the accessible portion of the report, included the suggestion that such methods could produce “misleading results” and create “unnecessary concern.”
The source article reports that USP, in its 2023 white paper, criticized certain outside testing approaches by labeling them as unvalidated and potentially prone to generating misleading outcomes. The STAT piece attributes this language to the white paper and identifies those phrases as central to the dispute that Valisure has raised in court.
Valisure contends that the white paper’s language was deployed in a manner intended to portray USP’s own testing methods as “inherently and universally safe” while implying that other testing approaches—specifically those used by Valisure—could undermine public confidence in medicines. The lab alleges that USP’s statements were not merely technical critiques but served to promote trust in a system that, Valisure says, “financially benefits” USP.
The accessible portion of the article states that Valisure filed suit in a U.S. court, claiming USP made false and misleading remarks about its testing methods. The reporting by Ed Silverman for STAT was published on Aug. 14, 2026. Beyond the summarized allegations and the identification of the 2023 white paper as the disputed document, the portion of the article available without subscription does not provide additional specifics from the lawsuit filing, such as exact legal claims, remedies sought, or direct quotations from the complaint or from USP responding to the suit.
The STAT piece containing this reporting is marked as a STAT+ exclusive. The accessible excerpt presents the core allegations that frame the dispute: Valisure’s assertion that USP called its testing methods unvalidated and potentially misleading in a 2023 white paper, and Valisure’s claim that USP promoted its own methods and financial interests. The article indicates that further details and in-depth coverage are available to STAT+ subscribers; those additional specifics were not included in the publicly available excerpt.
The publicly accessible portion of the source provides a summary of the dispute’s central allegations but does not report on USP’s response to the lawsuit, the precise legal causes of action Valisure asserted, the procedural posture of the case, or additional documentary evidence that may be cited in the filing. Any such details were not reported in the excerpted content and therefore cannot be restated here.
In brief, Valisure has initiated legal action alleging that U.S. Pharmacopeia (USP) made false and misleading statements in a 2023 white paper by characterizing Valisure’s testing approaches as “unvalidated” and prone to producing “misleading results.” Valisure frames the white paper as promoting USP’s own testing methods and advancing a system from which USP “financially benefits.” The story was reported by Ed Silverman for STAT on Aug. 14, 2026 and is identified as a STAT+ exclusive; full article content and additional reporting were behind the subscription paywall and were not included in the accessible source material.